Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial

We conducted a randomized, open-label, parallel-controlled, multicenter trial on the use of Shuanghuanglian (SHL), a traditional Chinese patent medicine, in treating cases of COVID-19. A total of 176 patients received SHL by three doses (56 in low dose, 61 in middle dose, and 59 in high dose) in add...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Li, Wen, Zheng, Hu, Xiaowen, Tang, Wei, Wang, Haisheng, Zhou, Ling, Wu, Lujin, Wang, Hong, Xu, Chang, Xu, Xizhen, Xiao, Zhichao, Li, Zongzhe, Li, Chene, Liu, Yujian, Duan, Jialin, Chen, Chen, Li, Dan, Zhang, Runhua, Li, Jinliang, Yi, Yongxiang, Huang, Wei, Chen, Yanyan, Zhao, Jianping, Zuo, Jianping, Weng, Jianping, Jiang, Hualiang, Wang, Dao Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079840/
https://www.ncbi.nlm.nih.gov/pubmed/33909260
http://dx.doi.org/10.1007/s11684-021-0853-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079840/
https://www.ncbi.nlm.nih.gov/pubmed/33909260
http://dx.doi.org/10.1007/s11684-021-0853-6

Ejemplares similares